Add like
Add dislike
Add to saved papers

Plasmonic ELISA based on the controlled growth of silver nanoparticles.

Nanoscale 2016 October 7
Herein, we demonstrate a plasmonic ELISA based on the alkaline phosphatase (ALP)-mediated growth of silver nanoparticles (AgNPs) for the sensitive, rapid, and naked-eye detection of cancer biomarkers in clinical serum samples. This approach was used to measure the low-abundance alpha fetal protein (AFP) in clinical sera, which demonstrates its great capability in the differentiation of cancers and evaluation of therapeutic responses. Impressively, the readout of the plasmonic assay depends on the rapid formation of Ag colloidal solutions with various degrees of yellow color, which can be distinguished by the naked eye, without the need for sophisticated platforms. The limit of detection of the plasmonic ELISA for alpha fetal protein (AFP) can be as low as 0.23 ng mL-1 , which is approximately 10 folds lower than that of conventional ELISA. This plasmonic ELISA opens a new avenue for the early detection of cancers and monitoring of cancer reoccurrence especially in resource-poor regions where convenient diagnostic tools are highly desirable.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app